ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

ClinicalTrials.gov ID: NCT00483756

Public ClinicalTrials.gov record NCT00483756. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients

Study identification

NCT ID
NCT00483756
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
338 participants

Conditions and interventions

Interventions

  • CP-690,550 Drug
  • Cyclosporine Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2007
Primary completion
Jan 31, 2010
Completion
Mar 31, 2010
Last update posted
Mar 13, 2013

2007 – 2010

United States locations

U.S. sites
37
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Palo Alto California 94304
Pfizer Investigational Site San Diego California 92123
Pfizer Investigational Site San Francisco California 94115
Pfizer Investigational Site San Francisco California 94143
Pfizer Investigational Site Stanford California 94305
Pfizer Investigational Site Aurora Colorado 80045
Pfizer Investigational Site New Haven Connecticut 06504
Pfizer Investigational Site New Haven Connecticut 06510
Pfizer Investigational Site Gainesville Florida 32610
Pfizer Investigational Site Gainsville Florida 32610
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site Chicago Illinois 60611
Pfizer Investigational Site Chicago Illinois 60637
Pfizer Investigational Site Baltimore Maryland 21201
Pfizer Investigational Site Boston Massachusetts 02215
Pfizer Investigational Site Springfield Massachusetts 01107
Pfizer Investigational Site Springfield Massachusetts 01199
Pfizer Investigational Site Ann Arbor Michigan 48109
Pfizer Investigational Site Detroit Michigan 48202
Pfizer Investigational Site Rochester Minnesota 55905
Pfizer Investigational Site St Louis Missouri 63110
Pfizer Investigational Site Livingston New Jersey 07039
Pfizer Investigational Site New York New York 10029
Pfizer Investigational Site Valhalla New York 10595
Pfizer Investigational Site Chapel Hill North Carolina 27514
Pfizer Investigational Site Chapel Hill North Carolina 27599-7155
Pfizer Investigational Site Chapel Hill North Carolina 27599-7211
Pfizer Investigational Site Chapel Hill North Carolina 27599-7360
Pfizer Investigational Site Portland Oregon 97239
Pfizer Investigational Site Philadelphia Pennsylvania 19102
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Dallas Texas 75204
Pfizer Investigational Site Dallas Texas 75246
Pfizer Investigational Site Fort Worth Texas 76104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00483756, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2013 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00483756 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →